Skip to main content
C4 Therapeutics, Inc. logo

C4 Therapeutics, Inc. — Investor Relations & Filings

Ticker · CCCC ISIN · US12529R1077 US Manufacturing
Open in API
Filings indexed 497 across all filing types
Latest filing 2020-10-02 Director's Dealing
Country US United States of America
Listing US CCCC

About C4 Therapeutics, Inc.

https://c4therapeutics.com/

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of a new class of small-molecule medicines through targeted protein degradation (TPD). The company's proprietary TORPEDO (Target Oriented Protein Degrader Optimizer) platform is utilized to create therapeutics that selectively destroy disease-causing proteins. C4 Therapeutics' primary focus is on developing treatments for cancer and other diseases. Its clinical pipeline includes investigational candidates such as cemsidomide (CFT7455) for hematologic malignancies, CFT8919 for solid tumors with specific genetic mutations, and CFT1946 for BRAF V600 mutant cancers.

Recent filings

Filing Released Lang Actions
FORM 3 SUBMISSION
Director's Dealing
2020-10-02 English
FORM 3 SUBMISSION
Director's Dealing
2020-10-02 English
FORM 3 SUBMISSION
Director's Dealing
2020-10-02 English
S-1MEF
Regulatory Filings Classification · 100% confidence The document is a Form S-1 Registration Statement filed with the SEC, specifically a Rule 462(b) filing to increase the number of shares offered in a public offering. It is a regulatory filing related to securities registration and offering, not a financial report, earnings release, or management discussion. The document includes legal opinions, consents, and signatures but does not contain financial statements or management analysis. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance document related to securities registration.
2020-10-02 English
Regulatory Filings 2020
Regulatory Filings
2020-10-01 English
Regulatory Filings 2020
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the SEC regarding a Registration Statement on Form S-1 for C4 Therapeutics, Inc. It discusses the distribution of a Preliminary Prospectus and requests acceleration of the effectiveness of the Registration Statement. This is related to securities offering and underwriting activities, not a financial report or earnings release. The document is short (1707 characters) and is a correspondence related to a regulatory filing for a securities registration. Therefore, it fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and filings that do not fit other categories.
2020-09-29 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.